Compare Stocks: STOK, ALKS, SYRE, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$46.10 -1.7%	$50.56	$25.17 ▼ $55.67	$7.73B	0.31	1.30 million shs	1.06 million shs
RYTM Rhythm Pharmaceuticals	$102.74 -2.0%	$109.60	$74.50 ▼ $122.20	$7.04B	1.97	506,335 shs	466,904 shs
STOK Stoke Therapeutics	$29.81 -0.6%	$31.17	$19.55 ▼ $40.22	$1.92B	1.23	846,612 shs	714,010 shs
SYRE Spyre Therapeutics	$88.98 +2.0%	$98.05	$14.51 ▼ $110.18	$7.82B	2.99	1.09 million shs	803,823 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-2.76%	-4.69%	+7.71%	+53.67%
RYTM Rhythm Pharmaceuticals	0.00%	-4.13%	-8.35%	+18.91%	+1.03%
STOK Stoke Therapeutics	0.00%	-5.72%	-6.64%	-0.67%	+50.78%
SYRE Spyre Therapeutics	0.00%	-1.53%	-13.96%	+20.81%	+429.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$46.10 -1.7%	$50.56	$25.17 ▼ $55.67	$7.73B	0.31	1.30 million shs	1.06 million shs
RYTM Rhythm Pharmaceuticals	$102.74 -2.0%	$109.60	$74.50 ▼ $122.20	$7.04B	1.97	506,335 shs	466,904 shs
STOK Stoke Therapeutics	$29.81 -0.6%	$31.17	$19.55 ▼ $40.22	$1.92B	1.23	846,612 shs	714,010 shs
SYRE Spyre Therapeutics	$88.98 +2.0%	$98.05	$14.51 ▼ $110.18	$7.82B	2.99	1.09 million shs	803,823 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-2.76%	-4.69%	+7.71%	+53.67%
RYTM Rhythm Pharmaceuticals	0.00%	-4.13%	-8.35%	+18.91%	+1.03%
STOK Stoke Therapeutics	0.00%	-5.72%	-6.64%	-0.67%	+50.78%
SYRE Spyre Therapeutics	0.00%	-1.53%	-13.96%	+20.81%	+429.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	18.36% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	37.35% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	48.44% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	23.28% Upside

Current Analyst Ratings Breakdown

Latest STOK, ALKS, SYRE, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	SYRE Spyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/26/2026	SYRE Spyre Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$135.00 ➝ $127.00
8/26/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$130.00 ➝ $123.00
8/26/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$132.00 ➝ $121.00
8/21/2026	STOK Stoke Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$40.00
8/11/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$112.00 ➝ $132.00
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	STOK Stoke Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	SYRE Spyre Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.64	$1.67 per share	27.53	$10.78 per share	4.28
RYTM Rhythm Pharmaceuticals	$189.76M	37.10	N/A	N/A	$1.50 per share	68.49
STOK Stoke Therapeutics	$184.42M	10.43	N/A	N/A	$5.36 per share	5.56
SYRE Spyre Therapeutics	$890K	8,792.02	N/A	N/A	$10.86 per share	8.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	121.32	192.08	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest STOK, ALKS, SYRE, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
STOK Stoke Therapeutics	N/A	7.69	7.69
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
RYTM Rhythm Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
RYTM Rhythm Pharmaceuticals	5.90%
STOK Stoke Therapeutics	9.60%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
STOK Stoke Therapeutics	100	64.53 million	58.33 million	Optionable
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable

STOK, ALKS, SYRE, and RYTM Headlines

Recent News About These Companies

Spyre Therapeutics Announces Grants of Inducement Awards

September 4 at 4:01 PM | globenewswire.com

Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of Stock

September 4 at 7:22 AM | insidertrades.com